747 results match your criteria Applied Health Economics and Health Policy [Journal]


Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations.

Appl Health Econ Health Policy 2019 Feb 4. Epub 2019 Feb 4.

Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Background And Objective: The economic burden of providing maintenance dialysis to those with end-stage kidney disease continues to increase. Home dialysis, including both haemodialysis and peritoneal dialysis, is commonly assumed to be more cost effective than facility dialysis, with some countries adopting a home-first policy in an attempt to reduce costs. However, the cost effectiveness of this approach is uncertain. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-00455-2
Publisher Site
http://dx.doi.org/10.1007/s40258-018-00455-2DOI Listing
February 2019
1 Read

Authors' Reply to Mintz: "Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model".

Appl Health Econ Health Policy 2019 Jan 25. Epub 2019 Jan 25.

Transfusion Medicine, Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-00459-yDOI Listing
January 2019

Comment on: "Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model".

Authors:
Paul Mintz

Appl Health Econ Health Policy 2019 Jan 25. Epub 2019 Jan 25.

Verax Biomedical, Marlborough, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-00458-zDOI Listing
January 2019

Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique.

Appl Health Econ Health Policy 2019 Jan 25. Epub 2019 Jan 25.

Macquarie University Centre for the Health Economy, Sydney, NSW, Australia.

Background: Permanent childhood hearing loss is one of the most common birth conditions associated with speech and language delay. A hearing screening can result in early detection and intervention for hearing loss.

Objectives: To update and expand previous systematic reviews of economic evaluations of childhood hearing screening strategies, and explore the methodological differences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-00456-1DOI Listing
January 2019
2 Reads

Vaccination: Is There a Place for Penalties for Non-compliance?

Appl Health Econ Health Policy 2019 Jan 24. Epub 2019 Jan 24.

Department of Philosophy, University College London, London, UK.

The introduction of punitive measures to control outbreaks of measles in Europe has sparked debate and public protest about the ethical justification of penalties and exclusionary processes for non-immunisation. This article advances an ethics framework related to compulsory vaccination policies, which we use to analyse three case studies: of mandatory policies that are enforced by fines; of policies that require vaccination for the provision of social goods; and of community-led policies in which communities themselves decide how to enforce vaccination compliance. We report on contemporary, ongoing and past measures that have been used to increase vaccine uptake, consider their rationale and the related public responses, elaborate on socio-cultural and contextual influences, and discuss the ethical justification for mandatory vaccination. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-019-00460-z
Publisher Site
http://dx.doi.org/10.1007/s40258-019-00460-zDOI Listing
January 2019
7 Reads

The Value of Further Research: The Added Value of Individual-Participant Level Data.

Appl Health Econ Health Policy 2019 Jan 23. Epub 2019 Jan 23.

Centre for Health Economics, The University of York, York, UK.

Judgements based on average cost-effectiveness estimates may disguise significant heterogeneity in net health outcomes. Decisions about coverage of new interventions are often more efficient when they consider between-patient heterogeneity, which is usually operationalized as different selections for different subgroups. While most model-based cost-effectiveness studies are populated with aggregated-level sub-group estimates, individual-level data are recognized as the best source of evidence to produce unbiased and efficient estimates to explore this heterogeneity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-019-00462-xDOI Listing
January 2019

Thopaz+ Portable Digital System for Managing Chest Drains: A NICE Medical Technology Guidance.

Appl Health Econ Health Policy 2019 Jan 23. Epub 2019 Jan 23.

Cedar, Cardiff and Vale University Health Board, Cardiff, Wales, UK.

The Thopaz+ portable digital system was evaluated by the Medical Technologies Advisory Committee (MTAC) of the National Institute for Health and Care Excellence (NICE). The manufacturer, Medela, submitted a case for the adoption of Thopaz+ that was critiqued by Cedar, on behalf of NICE. Due to a lack of clinical evidence submitted by the manufacturer, Cedar carried out its own literature search. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-019-00461-yDOI Listing
January 2019
1 Read

ReCell Spray-On Skin System for Treating Skin Loss, Scarring and Depigmentation after Burn Injury: A NICE Medical Technology Guidance.

Appl Health Econ Health Policy 2019 Jan 11. Epub 2019 Jan 11.

Cedar, Cardiff and Vale University Health Board, Cardiff Medicentre, Cardiff, CF14 4UJ, UK.

The gold standard treatment for deep burns is an autologous skin graft; in larger burns this may be meshed to increase the area covered. However, long-term aesthetic and functional outcomes of graft scars may be poor. ReCell is a medical device that processes skin samples in the operating theatre into a cell suspension to be sprayed or dripped onto a wound. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-00457-0DOI Listing
January 2019
4 Reads

Real-World Cost Effectiveness of Mandatory Folic Acid Fortification of Bread-Making Flour in Australia.

Appl Health Econ Health Policy 2019 Jan 8. Epub 2019 Jan 8.

Centre for Health Economics Research and Evaluation, University of Technology Sydney, PO Box 123, Broadway, Sydney, NSW, 2007, Australia.

Background: In 2009, mandatory folic acid fortification of bread-making flour was introduced in Australia to reduce the birth prevalence of preventable neural tube defects (NTDs) such as spina bifida. Before the introduction of the policy, modelling predicted a reduction of 14-49 NTDs each year.

Objective: Using real-world data, this study provides the first ex-post evaluation of the cost effectiveness of mandatory folic acid fortification of bread-making flour in Australia. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-00454-3
Publisher Site
http://dx.doi.org/10.1007/s40258-018-00454-3DOI Listing
January 2019
8 Reads

The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort.

Appl Health Econ Health Policy 2018 Dec 31. Epub 2018 Dec 31.

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, BS8 2PS, UK.

Background: High adiposity is associated with higher risks for a variety of adverse health outcomes, including higher rates of age-adjusted mortality and increased morbidity. This has important implications for the management of healthcare systems, since the endocrinal, cardiometabolic and other changes associated with increased adiposity may be associated with substantial healthcare costs.

Methods: We studied the association between various measures of adiposity and inpatient hospital costs through record linkage between UK Biobank and records of inpatient care in England and Wales. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0450-2DOI Listing
December 2018
1 Read

Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.

Appl Health Econ Health Policy 2018 Dec 10. Epub 2018 Dec 10.

Discipline of Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, Faculty of Medicine and Health, The University of Newcastle, MS108, Medical Sciences Building, University Drive, Callaghan, 2308, NSW, Australia.

Objectives: To assess the cost-effectiveness of nivolumab for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) progressed on or after platinum-based chemotherapy using a modelled economic evaluation.

Methods: Both partition survival (PS) and Markov models, comprised of three health states, were adopted to evaluate the cost-effectiveness of nivolumab compared to docetaxel from an Australian healthcare system perspective with a 6-year time horizon. Reconstructed individual patient data (IPD) were derived from published Kaplan-Meier curves from the pivotal trial for overall survival (OS) and progression-free survival (PFS) using a validated algorithm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0452-0DOI Listing
December 2018
2 Reads

Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes.

Appl Health Econ Health Policy 2018 Dec 5. Epub 2018 Dec 5.

Delta Hat Limited, 212 Tamworth Road, Nottingham, NG10 3GS, UK.

Background: When pharmaceuticals are administered based on patient characteristics (for example weight or body surface area), an amount of product will be unused and must be disposed of. This wastage represents inefficiency and can distort decision making.

Methods: We present a method for the analysis of optimum fill volumes of pharmaceuticals to minimise wastage across a patient population, using publicly available data. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0444-0
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0444-0DOI Listing
December 2018
2 Reads

A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study.

Appl Health Econ Health Policy 2018 Dec 3. Epub 2018 Dec 3.

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Paris-Saclay University, 2, avenue de la Source de la Bièvre, 78180, Montigny-Le-Bretonneux, France.

Background And Objective: Antimicrobial resistance (AMR) has become one of the biggest threats to global public health given its association with mortality, morbidity and cost of health care. However, little is known on the economic burden of hospitalization attributable to AMR from a public health insurance perspective. We assessed the excess costs to the French public health insurance system attributable to AMR infections in hospitals. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0451-1
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0451-1DOI Listing
December 2018
15 Reads

Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.

Appl Health Econ Health Policy 2018 Nov 28. Epub 2018 Nov 28.

Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA.

Background: Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0442-2DOI Listing
November 2018
13 Reads

Comment on: "Does MCDA Trump CEA?"

Appl Health Econ Health Policy 2019 Feb;17(1):123-124

Department of Health Policy and LSE Health, London School of Economics and Political Science, Houghton Street, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0445-zDOI Listing
February 2019
1 Read

Cost Effectiveness of New Diagnostic Tools for Cutaneous Leishmaniasis in Afghanistan.

Appl Health Econ Health Policy 2018 Nov 21. Epub 2018 Nov 21.

ISGlobal, Hospital-Clínic-Universitat de Barcelona, Carrer Rosselló 132, 08036, Barcelona, Spain.

Background And Objectives: Cutaneous leishmaniasis is responsible for chronic and disfiguring skin lesions resulting in morbidity and social stigma. The gold standard to diagnose cutaneous leishmaniasis is microscopy but has a variable sensitivity and requires trained personnel. Using four scenarios, the objective of this study is to compare the cost effectiveness of microscopy with two new tools: Loopamp™ Leishmania Detection Kit (LAMP) and CL Detect™ Rapid Test (RDT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0449-8DOI Listing
November 2018
7 Reads

Authors' Reply to Angelis and Kanavos: "Does MCDA Trump CEA?"

Appl Health Econ Health Policy 2019 Feb;17(1):125

Department of Economics and Related Studies and Center for Health Economics, University of York, York, YO10 5DD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0446-yDOI Listing
February 2019
9 Reads

Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance.

Appl Health Econ Health Policy 2019 Feb;17(1):25-34

Cedar, Cardiff and Vale University Health Board, Cardiff, UK.

The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluation Programme, for the management of bowel dysfunction. The company, Coloplast, submitted a case for adoption of the technology, claiming that the technology improves the severity of chronic constipation or faecal incontinence and improves quality of life for people with bowel dysfunction. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0447-x
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0447-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345726PMC
February 2019
17 Reads

The Effect of Medical Insurance on Outpatient Visits by the Elderly: An Empirical Study with China Health and Retirement Longitudinal Study Data.

Appl Health Econ Health Policy 2018 Nov 9. Epub 2018 Nov 9.

Key Laboratory of Advanced Theory and Application in Statistics and Data Science, East China Normal University, Ministry of Education, Shanghai, China.

Background: As the largest developing country in the world, China is still on its way towards building an adequate system of health insurance through continuous reforms. For the elderly in China, an effective medical security system might be especially helpful.

Objective: This study investigates the effect of medical insurance on outpatient visits by elderly Chinese in order to identify effective policies to improve the Chinese medical security system. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0443-1
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0443-1DOI Listing
November 2018
4 Reads

Comment on: "The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review".

Appl Health Econ Health Policy 2018 Oct 29. Epub 2018 Oct 29.

Centro de Excelencia en Estudios Económicos y Sociales en Salud, Universidad San Ignacio de Loyola (USIL), Avenida La Fontana 550, Lima, Peru.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0441-3
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0441-3DOI Listing
October 2018
9 Reads

Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review.

Appl Health Econ Health Policy 2018 Oct 27. Epub 2018 Oct 27.

Department of Health Sciences and Health Policy, University of Lucerne, Lucerne, Switzerland.

Objectives: The aim of this review is to assess the current state of empirical research regarding the effectiveness of national pricing regulations of the patent-protected market for prescription pharmaceuticals. Effectiveness is understood to be the capacity of policies to have a desired impact on outcomes, such as health status, patient access, healthcare expenditure, and research investments, among others.

Methods: A systematic review of the published literature on pricing regulations in OECD countries was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0437-zDOI Listing
October 2018
1 Read

Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance.

Appl Health Econ Health Policy 2018 Oct 26. Epub 2018 Oct 26.

LSE Health, Department of Health Policy, London School of Economics and Political Science, Houghton Street, 20 Houghton St, London, WC2A 2AE, UK.

Background: The Medical Technologies Evaluation Programme (MTEP) of NICE in England aims to evaluate medical devices that are deemed to be cost-saving or cost-neutral and produce Medical Technology Guidance (MTG) to encourage their adoption.

Objective: To review the MTGs since MTEP's inception in 2009 until February 2017.

Methods: One researcher assessed all published MTGs and extracted data on the clinical and economic evidence supporting each technology. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0438-y
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0438-yDOI Listing
October 2018
24 Reads

Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use.

Appl Health Econ Health Policy 2018 Oct 25. Epub 2018 Oct 25.

Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471, Adelaide, SA, 5001, Australia.

Objectives: To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies.

Methods: Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (December 2012), and ranibizumab initiators in the year before aflibercept listing. The dispensing rates for each cohort were calculated, and their demographic and clinical characteristics compared using Kruskal-Wallis tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0440-4DOI Listing
October 2018
1 Read

Family Spillover Effects in Pediatric Cost-Utility Analyses.

Appl Health Econ Health Policy 2018 Oct 22. Epub 2018 Oct 22.

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, #63, Boston, MA, 02111, USA.

Background: Childhood illness can impose significant costs and health strains on family members, but these are not routinely captured by pediatric economic evaluations. This review investigated how family "spillover effects" related to costs and health outcomes are considered in pediatric cost-utility analyses (CUAs).

Methods: We reviewed pediatric CUAs published between 2000 and 2015 using the Tufts Medical Center Cost-effectiveness Analysis (CEA) Registry and the Pediatric Economic Database Evaluation (PEDE) Registry. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0436-0
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0436-0DOI Listing
October 2018
11 Reads

A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges.

Appl Health Econ Health Policy 2019 Feb;17(1):35-46

Exponent Inc, 3440 Market Street, Suite 600, Philadelphia, PA, 19104, USA.

Background: Advanced heart failure (HF) can be treated conservatively or aggressively, with left ventricular assist devices (LVADs) and heart transplant (HT) being the most aggressive strategies.

Objective: The goal of this review was to identify, describe, critique and summarize published cost-effectiveness analyses on LVADs for adults with HF.

Methods: We conducted a literature search using PubMed and ProQuest DIALOG databases to identify English-language publications from 2006 to 2017 describing cost-effectiveness analyses of LVADs and reviewed them against inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0439-xDOI Listing
February 2019
1 Read

The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece.

Appl Health Econ Health Policy 2019 Feb;17(1):111-121

Department οf Health Services Organization and Management, National School οf Public Health, Athens, Greece.

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death worldwide, imposing a substantial socioeconomic burden on societies and patients due to the long-term management required.

Objective: To assess the economic burden of COPD in Greece and its potential determinants.

Methods: A population-based, random-digit dialled, telephone nationwide survey was conducted to recruit patients with COPD in Greece (N = 351). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0431-5
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0431-5DOI Listing
February 2019
10 Reads

Re-design of Aged Care Environments is Key to Improved Care Quality and Cost Effective Reform of Aged and Health System Care.

Appl Health Econ Health Policy 2018 Oct 16. Epub 2018 Oct 16.

Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0435-1
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0435-1DOI Listing
October 2018
5 Reads

Reliability and Validity of the Contingent Valuation Method for Estimating Willingness to Pay: A Case of In Vitro Fertilisation.

Appl Health Econ Health Policy 2019 Feb;17(1):103-110

National Perinatal Epidemiology and Statistics Unit, Centre for Big Data Research in Health and School of Women's and Children's Health, University of New South Wales, Sydney, Australia.

Background: The contingent valuation (CV) method is an alternative approach to typical health economic methods for valuing interventions that have both health and non-health outcomes. Fertility treatment, such as in vitro fertilisation (IVF), fall into this category because of the significant non-health outcomes associated with having children.

Aim: To estimate the general population's willingness to pay (WTP) for one cycle of IVF and one year of IVF treatment, and to test the reliability and validity of a CV instrument. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0433-3
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0433-3DOI Listing
February 2019
8 Reads

Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System.

Appl Health Econ Health Policy 2019 Feb;17(1):93-101

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Background: Early awareness and alert systems have been established in many countries but evidence on their ability to accurately prioritize new medicines (for early assessment) is limited.

Objective: The purpose of this study was to assess whether the Swedish Early Awareness and Alert System identified and prioritized (i.e. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0434-2
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0434-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346078PMC
February 2019
10 Reads

Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States.

Appl Health Econ Health Policy 2019 Feb;17(1):77-91

Division of Population Health, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 4770 Buford Highway NE, Mailstop F-78, Atlanta, GA, 30341, USA.

Background: Few studies have addressed recent trends in hospitalization costs for inflammatory bowel disease (IBD).

Objective: We explored trends and described patient and hospital factors associated with hospitalization costs for IBD.

Methods: Using data from the 2003-2014 National Inpatient Sample for adults aged ≥ 18 years, we estimated costs using multivariable linear models and assessed linear trends by time periods using piecewise linear regressions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0432-4DOI Listing
February 2019
11 Reads

Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda.

Appl Health Econ Health Policy 2019 Feb;17(1):65-76

Unit of PharmacoTherapy, Epidemiology and Economics (PTE2), Department of Pharmacy, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands.

Objectives: The aim was to estimate the long-term cost-effectiveness of improved family planning interventions to reduce the unmet need in low- and middle-income countries, with Indonesia and Uganda as reference cases.

Methods: The analysis was performed using a Markov decision analytic model, where current situation and several scenarios to reduce the unmet need were incorporated as the comparative strategies. Country-specific evidence was synthesized from the demographic and health survey and published studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0430-6DOI Listing
February 2019
1 Read

Budget Impact Analysis of a Renal Point-of-Care Test in Dutch Community Pharmacies to Prevent Antibiotic-Related Hospitalizations.

Appl Health Econ Health Policy 2019 Feb;17(1):55-63

Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.

Objectives: Medication errors that lead to adverse drug reactions are a key cause of unintentional patient harm and subsequent economic burden. To prevent this, measurement of renal function could be considered. The aim of this study was to determine the budget impact of obtaining and evaluating renal function in community pharmacies in the Netherlands to prevent antibiotic-related hospitalizations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0426-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345725PMC
February 2019
2 Reads

Level of Evidence in Economic Evaluations of Left Atrial Appendage Closure Devices: A Systematic Review.

Appl Health Econ Health Policy 2018 Dec;16(6):793-802

Pharmacy Department, Georges Pompidou European Hospital, AP-HP, 20 rue Leblanc, 75015, Paris, France.

Objectives: The objective of the present work was to assess the level of evidence in economic evaluations of percutaneous left atrial appendage closure devices, and to test the complementarity of three different tools for assessing the quality of economic evaluations.

Methods: We conducted a systematic review of articles in English or French listed in MEDLINE, Embase, Cochrane, the Cost-Effectiveness Analysis registry and the National Health Service Economic Evaluation Database. We included only economic evaluations concerning left atrial appendage closure devices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0429-zDOI Listing
December 2018
4 Reads

Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040.

Appl Health Econ Health Policy 2018 Dec;16(6):847-857

Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Introduction: The World Health Organisation (WHO) has set ambitious goals to reduce the global disease burden associated with, and eventually eliminate, viral hepatitis.

Objective: To assist with achieving these goals and to inform the development of a national strategic plan for Malaysia, we estimated the long-term burden incurred by the care and management of patients with chronic hepatitis C virus (HCV) infection. We compared cumulative healthcare costs and disease burden under different treatment cascade scenarios. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0425-3DOI Listing
December 2018
2 Reads

Ethically Acceptable Compensation for Living Donations of Organs, Tissues, and Cells: An Unexploited Potential?

Appl Health Econ Health Policy 2019 Feb;17(1):1-14

Department of Economics, Copenhagen Business School, Porcelænshaven 16A, 2000, Frederiksberg, Denmark.

The number of living donations of human organs, tissues, and cells falls far short of the need. Market-like arrangements to increase donation rates have been proposed, but they are broadly considered unacceptable due to ethical concerns and are therefore not policy relevant in most countries. The purpose of this paper is to explore a different approach to increasing living donations, namely through the use of ethically acceptable compensation of donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0421-7DOI Listing
February 2019
11 Reads

Effects of the ACA on Preventive Care Disparities.

Appl Health Econ Health Policy 2018 Dec;16(6):859-869

Mezrah Consulting, 5350 West Kennedy Boulevard, Suite Two, Tampa, FL, 33609, USA.

Background: The Affordable Care Act (ACA) requires non-grandfathered private insurance plans, starting with plan years on or after September 23rd, 2010, to provide certain preventive care services without any cost sharing in the form of deductibles, copayments or co-insurance. This requirement may affect racial and ethnic disparities in preventive care as it provides the largest copay reduction in preventive care.

Objectives: We ask whether the ACA's free preventive care benefits are associated with a reduction in racial and ethnic disparities in the utilization of four preventive services: cholesterol screenings, colonoscopies, mammograms, and Pap smears. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0423-5
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0423-5DOI Listing
December 2018
20 Reads

Potential Impact of Sweetener Input Tax on Public Health.

Appl Health Econ Health Policy 2018 Dec;16(6):749-751

Department of Agribusiness and Applied Economics, North Dakota State University, Richard H. Barry Hall 500, 811 2nd Ave. N., Fargo, ND, 58102, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0428-0DOI Listing
December 2018
3 Reads

The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.

Appl Health Econ Health Policy 2019 Feb;17(1):47-54

Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St., Suite 3030, Boston, MA, 02120, USA.

Background: Most new brand-name drugs are protected by patents from generic competition, but these patents are occasionally granted in error. Invalidating such patents has traditionally been accomplished via court litigation by generic manufacturers, which is expensive and time consuming. In 2011, Congress created an administrative alternative to court litigation of patents, called inter partes review, intended to be much faster and less expensive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0420-8DOI Listing
February 2019
20 Reads

Estimation of the Direct Cost of Poliomyelitis Rehabilitation Treatment to Pakistani Patients: A 53-Year Retrospective Study.

Appl Health Econ Health Policy 2018 Dec;16(6):871-888

Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Saudi Arabia.

Background: Pakistan is one of the last few countries in which poliomyelitis is endemic. Evidence indicates that out-of-pocket expenditures are a barrier to polio rehabilitation treatment, yet there are no reported figures related to the financial burden of this disease on patients in a recently polio-endemic country.

Objective: This study investigated direct costs attributed to rehabilitation treatment of poliomyelitis among Pakistani patients and reported its duration along with the socioeconomic status of poliomyelitis survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0422-6DOI Listing
December 2018
8 Reads

SecurAcath for Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance.

Appl Health Econ Health Policy 2018 Dec;16(6):779-791

King's Technology Evaluation Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK.

Central venous catheters are commonly used to deliver therapies and to monitor patients, and require securing at the point of percutaneous entry to avoid dislodgement. SecurAcath is a catheter securement device designed for central venous catheters. The National Institute for Health and Care Excellence, as a part of its Medical Technologies Evaluation Programme, selected this device for evaluation and invited the manufacturer, Interrad Medical, to submit clinical and economic evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0427-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244619PMC
December 2018
3 Reads

Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran.

Appl Health Econ Health Policy 2018 Dec;16(6):837-846

Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Objective: This study was aimed at estimating the value of the general population's willingness-to-pay (WTP) for one quality-adjusted life-year (QALY) in Iran.

Methods: Using multistage randomized cluster sampling, we recruited and interviewed 651 adult residents of Shiraz, south Iran. The mean age of the interviewees was 43. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0424-4
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0424-4DOI Listing
December 2018
19 Reads

Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method.

Appl Health Econ Health Policy 2019 Feb;17(1):15-24

Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden.

Costs of informal care account for a significant component of total societal costs for many chronic and disabling illnesses. Yet, costs associated with the provision of informal care is seldom included in economic evaluations of new health technologies, increasing the risk of suboptimal decisions on the allocation of resources from the perspective of society. Our objective was to propose a standardized questionnaire for the measurement, valuation, and estimation of caregiver indirect (productivity) and informal care costs as separate mutually exclusive subsets of total costs in cost-of-illness studies and as an input to economic evaluations from the societal perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0418-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346077PMC
February 2019
5 Reads

Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Appl Health Econ Health Policy 2018 Dec;16(6):765-778

Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USA.

Cost-of-illness (COI) studies often include the 'indirect' cost of lost production resulting from disease, disability, and premature death, which is an important component of the economic burden of chronic conditions assessed from the societal perspective. In most COI studies, productivity costs are estimated primarily as the economic value of production forgone associated with loss of paid employment (foregone gross earnings); some studies include the imputed value of lost unpaid work as well. This approach is commonly but imprecisely referred to as the human capital approach (HCA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0416-4DOI Listing
December 2018
2 Reads

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.

Appl Health Econ Health Policy 2018 Dec;16(6):803-817

Università del Piemonte Orientale, Novara, Italy.

Background: Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure-driven by high prices-will be unsustainable unless further reforms are enacted.

Objective: The aim of this paper is to provide more realistic expectations of pharmaceutical expenditure for all key stakeholder groups by estimating pharmaceutical expenditure at 'net' prices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0419-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244625PMC
December 2018
4 Reads

Use of Expert Judgement Across NICE Guidance-Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation.

Appl Health Econ Health Policy 2018 Dec;16(6):819-836

York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, UK.

Objectives: This study aimed to review current use of experts within National Institute for Health and Care Excellence (NICE) guidance-making programmes, identify improvements in use of expert judgement, and to assess tools and protocols to support the elicitation of information from experts for use by NICE.

Methods: The study comprised a review of NICE process guides; semi-structured interviews with individuals representing each NICE guidance-making programme and a comparison of the suitability of currently available tools and protocols for expert elicitation to the requirements of NICE programmes.

Results: Information elicited from experts and the way in which it is used varies across NICE guidance-making programmes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0415-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244638PMC
December 2018
2 Reads

Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.

Appl Health Econ Health Policy 2018 Dec;16(6):889-899

Center for Health Outcomes, Policy, and Economics, Rutgers University, 160 Frelinghuysen Road, Suite 417, Piscataway, NJ, 08854, USA.

Background: US FDA draft guidance includes pathogen reduction (PR) or secondary rapid bacterial testing (RT) in its recommendations for mitigating risk of platelet component (PC) bacterial contamination. An interactive budget impact model was created for hospitals to use when considering these technologies.

Methods: A Microsoft Excel model was built and populated with base-case costs and probabilities identified through literature search and a survey of US hospital transfusion service directors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0409-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244623PMC
December 2018
5 Reads

Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.

Appl Health Econ Health Policy 2018 Dec;16(6):753-763

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway Ave, Baltimore, MD, 21202, USA.

In 2018, the Medicare Part D catastrophic threshold is $5000 in out-of-pocket total drug spending incurred by the beneficiary. Above this, Medicare pays 80%, prescription drug plans (PDPs) pay 15%, and beneficiaries pay a 5% copay. However, recent growth in catastrophic spending is caused by expensive specialty drugs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-018-0417-3
Publisher Site
http://dx.doi.org/10.1007/s40258-018-0417-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244621PMC
December 2018
10 Reads

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.

Appl Health Econ Health Policy 2018 Oct;16(5):697-709

Department of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, 31270-901, Brazil.

Background: Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, few studies capture the cost of managing these patients within the Brazilian NHS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0408-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132453PMC
October 2018
9 Reads

Gun Policy in the United States: Evidence-Based Strategies to Reduce Gun Violence.

Appl Health Econ Health Policy 2018 Oct;16(5):579-581

Johns Hopkins Center for Gun Policy and Research, Baltimore, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-018-0413-7DOI Listing
October 2018
2 Reads